下段剖宫产术后手术部位感染的病原体及抗生素指南建议
该研究为大型回顾性研究,基于西澳大利亚医疗感染监测(HISWA)数据,分析2001至2021年西澳大利亚公立医院所有下段剖宫产(LUCS)术后手术部位感染(SSI)的病原体。共识别687例SSI患者,最常见病原体为甲氧西林敏感金黄色葡萄球菌(MSSA,30.4%)、耐甲氧西林金黄色葡萄球菌(MRSA,14.7%)、肠杆菌目(9.5%)、铜绿假单胞菌(9.3%)和路邓葡萄球菌(5.7%),A组和B组链球菌累计占5%以上。浅表SSI显著多于深部SSI,急诊LUCS后SSI显著更常见。作者认为现行澳大利亚指南对相当比例LUCS SSI患者可能不合适,有全身感染特征者应覆盖铜绿假单胞菌和MRSA,脓毒症或脓毒性休克危重患者应使用对AmpC/ESBL产肠杆菌目有活性的碳青霉烯类而非哌拉西林/他唑巴坦;路邓葡萄球菌可能是被低估的病原体,并强调伤口部位采样对指导目标性抗微生物治疗的重要性。
要点
- 687例LUCS术后SSI中,最常见病原体为MSSA(30.4%)、MRSA(14.7%)、肠杆菌目(9.5%)、铜绿假单胞菌(9.3%)、路邓葡萄球菌(5.7%)。
- 作者认为现行澳大利亚指南对相当比例LUCS SSI患者可能不合适;有全身感染特征者应使用覆盖铜绿假单胞菌和MRSA的抗生素。
- 作者认为脓毒症或脓毒性休克危重患者应使用对AmpC/ESBL产肠杆菌目有活性的碳青霉烯类,而非哌拉西林/他唑巴坦。
- 浅表SSI显著多于深部SSI,急诊LUCS后SSI显著更常见。
- 作者强调伤口部位采样对建立适当的目标性抗微生物治疗的重要性;路邓葡萄球菌可能是LUCS SSI中被低估的病原体。
适用人群与场景
- 2001至2021年西澳大利亚公立医院所有下段剖宫产(LUCS)术后手术部位感染(SSI)的住院患者,数据来自西澳大利亚医疗感染监测(HISWA)。
处置流程与药物剂量
- 作者认为,有全身感染特征的患者应接受对铜绿假单胞菌和MRSA有活性的抗生素治疗。
- 作者认为,有脓毒症或脓毒性休克特征的危重患者应使用对AmpC/ESBL产肠杆菌目有活性的碳青霉烯类药物,而非哌拉西林/他唑巴坦。
- 作者强调伤口部位采样以建立适当的目标性抗微生物治疗。
红旗征与不能漏的情况
- 有全身感染特征的患者,作者认为应覆盖铜绿假单胞菌和MRSA。
- 有脓毒症或脓毒性休克特征的危重患者,作者认为应使用对AmpC/ESBL产肠杆菌目有活性的碳青霉烯类,而非哌拉西林/他唑巴坦。
研究设计与关键结果
- 研究类型为大型回顾性研究,共识别687例LUCS术后SSI患者,时间跨度为2001至2021年。
- 最常见病原体或病原体组:MSSA 30.4%,MRSA 14.7%,肠杆菌目9.5%,铜绿假单胞菌9.3%,路邓葡萄球菌5.7%;A组和B组链球菌累计占5%以上。
- 浅表SSI数量显著多于深部SSI,急诊LUCS后SSI显著更常见。
证据类型、等级与局限
- 证据类型:大型回顾性研究,数据来自西澳大利亚医疗感染监测(HISWA)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,现行澳大利亚指南对相当比例LUCS SSI患者可能不合适。
- 作者认为,有全身感染特征的患者应接受覆盖铜绿假单胞菌和MRSA的抗生素治疗。
- 作者认为,有脓毒症或脓毒性休克特征的危重患者应使用对AmpC/ESBL产肠杆菌目有活性的碳青霉烯类,而非哌拉西林/他唑巴坦。
- 作者强调伤口部位采样对建立适当的目标性抗微生物治疗的重要性,并指出路邓葡萄球菌可能是LUCS SSI中被低估的病原体。
指南或共识出处
- 原文提及现行澳大利亚指南,但未给出具体指南名称。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Caesarean section surgical site infections (SSIs) have the potential to cause major complications however there remains a paucity of data on its microbiology and causative organisms.
AIMS: The aim of this study was to identify the organisms causing SSIs in hospitalised patients after lower uterine caesarean section (LUCS). Secondary aims included investigating the differences in organisms isolated from elective versus emergency caesarean sections, and to compare the microbiology of superficial and deep SSIs.
MATERIALS AND METHODS: This was a large retrospective study reviewing all SSIs after LUCS in Western Australian (WA) public hospitals from 2001 to 2021 with data obtained from the Healthcare Infection Surveillance of Western Australia (HISWA).
RESULTS: There were 687 patients identified with an SSI following LUCS over this twenty-year period. The five most common organisms or organism groups isolated were methicillin-susceptible Staphylococcus aureus (MSSA) (30.4%), methicillin-resistant Staphylococcus aureus (MRSA) (14.7%), Enterobacterales (9.5%), Pseudomonas aeruginosa (9.3%), Staphylococcus lugdunensis (5.7%). Group A and B Streptococcus were isolated cumulatively in more than 5% of cases. There were a significantly higher number of superficial SSIs than deep SSIs, and SSIs were significantly more common post emergency LUCS.
CONCLUSIONS: Current Australian guidelines may not be appropriate in a considerable proportion of patients with LUCS SSIs, and patients with systemic features of infection should receive antibiotics with activity against P. aeruginosa and MRSA. Critically ill patients with features of sepsis or septic shock should be administered a carbapenem agent which has activity against AmpC/ESBL producing Enterobacterales, instead of piperacillin/tazobactam. Staphylococcus lugdunensis may be an under recognised pathogen in LUCS SSIs. This study also highlighted the importance of wound site sampling in SSIs to establish appropriate directed antimicrobial therapy.
参考来源
- Yeo B, Clohessy P, Walczak A, et al. Pathogens Causing Surgical Site Infections After Lower Uterine Caesarean Sections and Recommendations for Antibiotic Guidelines. Aust N Z J Obstet Gynaecol. 2025. PMID: 40159722. doi:10.1111/ajo.70034
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。